PLA2G2D

Across TCGA pan-cancer cohorts, PLA2G2D mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PLA2G2D data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLA2G2D mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLA2G2D expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD and LSCC are the cancer types where PLA2G2D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.975	0.536	.001	17	view →
LSCC	DFS	Median	II,III,IV	1.000	0.485	.013	5	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PLA2G2D–LUAD (DFS)

Open the LUAD breakdown →